This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Nipd Genetics Public Company Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Alexia Eliades: Innovator in Tumor Biomarker Analysis
Introduction
Alexia Eliades is a prominent inventor based in Nicosia, Cyprus. She has made significant contributions to the field of tumor biomarker analysis, showcasing her expertise through her innovative patent.
Latest Patents
Alexia holds a patent titled "Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers." This invention provides methods for assessing tumor biomarkers using target-enriched multiplexed parallel analysis. The methods utilize Target Capture Sequences (TACS) to enrich for target sequences of interest, followed by massive parallel sequencing and statistical analysis of the enriched population. These methods can be applied to DNA samples from patients, such as tissue biopsies or plasma samples (liquid biopsies), for the detection of tumor biomarkers. This invention serves various purposes, including diagnosis, screening, therapy selection, and treatment monitoring. Additionally, kits for carrying out the methods of the invention are also provided.
Career Highlights
Alexia Eliades is associated with Nipd Genetics Public Company Ltd., where she continues to advance her research and innovations in the field of genetics and oncology.
Collaborations
She collaborates with notable colleagues, including George Koumbaris and Marios Ioannides, contributing to a dynamic research environment focused on improving cancer diagnostics.
Conclusion
Alexia Eliades is a trailblazer in the field of tumor biomarker analysis, with her innovative patent paving the way for advancements in cancer diagnostics and treatment. Her work exemplifies the impact of innovation in healthcare.